CD274 and non-small cell lung carcinoma: Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown improved overall survival compared to single-agent chemotherapy both in previously treated metastatic NSCLC patients (6, 7) and as first-line treatment in PD-L1–high NSCLC patients (8).